M. D. Anderson Cancer Center
Develop novel biomarkers and diagnostic strategies for the early detection of occult urinary bladder neoplasia and its progression from intraurothelial preneoplastic conditions to invasive cancer.
A multidisciplinary group focused on discovery and development of new markers for early detection of bladder cancer based on identification of molecular and epigenetic alterations in bladder cancer.
- Perform functional analyses and assessment of identified putative “forerunner genes” (ITM2B, P2RY5, and CHCl L) located contiguously to RBI as novel early detection biomarkers.
- Characterize other predicted forerunner gene on chromosomes 17p13, and 5q22-23 and assess them as potential biomarkers for bladder cancer detection.
- Investigate the contribution of genetic and epigenetic mechanisms in the functional inactivation of each of the genes to elucidate a comprehensive view of the role of forerunner genes in the malignant transformation process as potential biomarkers.
- STAKl5/BTAWAurora-A and its interacting genes as biomarkers for bladder cancer.
- Assemble a comprehensive panel of biomarkers based on STKl5/BTAWAurora-A, and similar genes associated with mitotic checkpoints, the forerunner genes (approximately 15 markers) and test there utility in early detection of bladder cancer.
Bodgan Czerniak, MD, Ph.D.
> University of Texas M.D. Anderson Cancer Center<br> Dept. of Pathology Box 085
> 1515 Holcombe Blvd.<br> Houston, TX 77030
Phone: (713) 794-1025
> Fax: (713) 792-4049<br> Email: email@example.com